Renal Cell Carcinoma
Conditions
Keywords
Sunitinib, Renal Cell Carcinoma, Therapeutic Drug Monitoring, Pharmacokinetic, Treatment toxicity
Brief summary
Sunitinib is an oral drug used for treatment of advanced kidney cancer. The standard dose is 50mg, but many patients require a dose decrease due to side-effects. Drug levels of sunitinib vary approximately 10-fold between patients. This study will measure blood levels of sunitinib and its metabolite, and correlate these with side-effects and the response to the treatment. The study aims to establish whether blood levels change with time, and see how useful blood levels are for monitoring patients treated with sunitinib.
Detailed description
Rationale: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor used for first-line systemic therapy in metastatic renal cell carcinoma. It is metabolised to a pharmacologically active metabolite, SU012662, which is of equal potency to the parent compound. At a standard 50mg daily dose, variability in plasma levels between patients is approximately ten-fold. In clinical trials, over 30% of patients require a dose reduction due to toxicity. However, some patients can tolerate up to 100mg without excessive toxicity. It is unknown if sunitinib clearance changes with time. Pre-clinical experiments observed tyrosine kinase inhibition at a plasma concentration of 50-100ng/ml. Design: This is a prospective non-randomized, Phase II clinical study. Decision to treat patients with single-agent sunitinib is pre-determined by treating specialists before entering this study. Toxicity and trough sunitinib/metabolite levels will be measured every six weeks during treatment. Aim: This study will prospectively examine the relationship between steady-state trough levels of sunitinib/metabolites and the time on treatment, in addition to changes in trough levels over time. Trough levels will also be correlated with other measures of efficacy and treatment-related toxicity. Furthermore, we aim to confirm that the putative target of 50ng/ml correlates with toxicity and time on sunitinib.
Interventions
None listed
Sponsors
Western Sydney Local Health District
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metastatic renal cell cancer treated with single agent sunitinib * No known primary liver disease and no other severe or uncontrolled concurrent medical conditions * Signed informed consent
Exclusion criteria
* Patients who are unable to sign informed consent * Patients unable to give blood * Patients who are pregnant, nursing or not using an effective contraception method * Patients who had bone-marrow-transplantation prior to sunitinib treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to treatment failure (time on sunitinib treatment) | Sunitinib duration (median) | This duration extends from the date the patient starts sunitinib until the date sunitinib is abandoned. The group with sunitinib concentration below the population median are expected to have a median Time to Treatment Failure (TTF) of approximately 8 months, compared with 14 months in those with sunitinib concentration above the population median. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity | Every 6 weeks | Pre-specified toxicities (BP, fatigue, diarrhoea, stomatitis, hand-foot syndrome) will be graded every 6 weeks |
| Overall survival | 2 years | Measured from the date of starting sunitinib treatment to the date of death from any cause |
| Progression-free survival | 2 years | Progression as determined by the clinician according to RECIST 1.1 definitions |
| Time to second line therapy | 2 years | Date of starting sunitinib treatment to the date further systemic therapy is started |
Countries
Australia
Contacts
Primary ContactHoward Gurney, MBBS, FRACP
Outcome results
None listed